IDEAYA Biosciences, Inc. IDYA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $157.52M+39.6% | $112.83M-62.3% | $298.93M+161% | $114.65M-11.8% | $130M+54.1% | ||
| $513.68M-2.4% | $526.56M+7.9% | $487.97M-12.1% | $555.09M-1.3% | $562.51M-5.0% | ||
| $696.11M+4.4% | $666.73M-16.9% | $802.66M+17.1% | $685.6M-3.1% | $707.87M+2.6% | ||
| $8.63M+5.1% | $8.22M+0.6% | $8.17M-7.3% | $8.82M-0.6% | $8.87M-1.1% | ||
| $1.03B-7.1% | $1.11B-6.4% | $1.19B+13.8% | $1.04B-5.4% | $1.1B-2.1% | ||
| $20.74M+17.9% | $17.58M-4.6% | $18.43M+6.7% | $17.27M-2.0% | $17.63M+14.3% | ||
| —— | —— | —— | —— | —— | ||
| $64.83M+10.2% | $58.82M-8.8% | $64.51M+16.6% | $55.34M+8.8% | $50.85M+10.4% | ||
| $93.08M+7.7% | $86.39M-7.2% | $93.1M+14.1% | $81.62M+6.7% | $76.51M+17.8% | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | ||
| -$835.08M-13.4% | -$736.54M-12.7% | -$653.27M+15.4% | -$772.51M-11.1% | -$695.02M-11.6% | ||
| $937.27M-8.4% | $1.02B-6.3% | $1.09B+13.8% | $959.65M-6.3% | $1.02B-3.3% | ||
| $1.03B-7.1% | $1.11B-6.4% | $1.19B+13.8% | $1.04B-5.4% | $1.1B-2.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are IDEAYA Biosciences, Inc.'s total assets?
- IDEAYA Biosciences, Inc. (IDYA) holds $1.0B in total assets, down 6.4% year over year.
- How much debt does IDEAYA Biosciences, Inc. have?
- IDEAYA Biosciences, Inc. carries $28.6M in total debt against $937.3M of shareholders' equity, a debt-to-equity ratio of 0.03.
- How much cash does IDEAYA Biosciences, Inc. have?
- IDEAYA Biosciences, Inc. holds $157.5M in cash and equivalents.
- Can IDEAYA Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 10.74 — current assets exceed current liabilities.
- Where does IDEAYA Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from IDEAYA Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
